Late stent thrombosis in a patient with CYP2C19*3/*17 genotype and clopidogrel high on-treatment platelet reactivity

Pharmacogenomics. 2018 Oct;19(15):1151-1157. doi: 10.2217/pgs-2018-0082. Epub 2018 Sep 7.

Abstract

Aim: Recurrent thrombotic events still occur despite dual antiplatelet therapy in patient's post percutaneous coronary intervention (PCI) could be attributed to high on-treatment platelet reactivity.

Methods: A 44-year-old male, who had staged PCI to left anterior descending (LAD) 2 weeks after an anterior MI, with a drug-coated stent was readmitted with new anterior STEMI 35 days later. Coronary angiogram revealed mid-stent thrombus in situ. He had further uncomplicated PCI. Platelet function testing and genotyping showed clopidogrel high on-treatment platelet reactivity and CYP2C19*3/*17 genotype. Ticagrelor was commenced.

Results & conclusion: This case study is the first reported in Malaysia to document a patient with a CYP2C19*3/*17 genotype presenting with a stent thrombosis after an uncomplicated index PCI procedure.

Keywords: CYP2C19*3/*17; late stent thrombosis; point-of-care genotyping.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Platelets / drug effects*
  • Clopidogrel / adverse effects*
  • Cytochrome P-450 CYP2C19 / genetics*
  • Drug-Eluting Stents / adverse effects
  • Genotype
  • Humans
  • Male
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Thrombosis / chemically induced*
  • Thrombosis / genetics*
  • Ticagrelor / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticagrelor